IMAB vs. INCR, RGLS, CRVO, IXHL, ACET, RPTX, DMAC, PRLD, PDSB, and SGMT
Should you be buying I-Mab stock or one of its competitors? The main competitors of I-Mab include InterCure (INCR), Regulus Therapeutics (RGLS), CervoMed (CRVO), Incannex Healthcare (IXHL), Adicet Bio (ACET), Repare Therapeutics (RPTX), DiaMedica Therapeutics (DMAC), Prelude Therapeutics (PRLD), PDS Biotechnology (PDSB), and Sagimet Biosciences (SGMT). These companies are all part of the "pharmaceutical preparations" industry.
InterCure (NASDAQ:INCR) and I-Mab (NASDAQ:IMAB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, community ranking, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.
InterCure has higher revenue and earnings than I-Mab.
I-Mab received 53 more outperform votes than InterCure when rated by MarketBeat users. However, 100.00% of users gave InterCure an outperform vote while only 62.92% of users gave I-Mab an outperform vote.
In the previous week, I-Mab's average media sentiment score of 1.02 beat InterCure's score of 0.00 indicating that InterCure is being referred to more favorably in the media.
InterCure has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500. Comparatively, I-Mab has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.
8.3% of InterCure shares are held by institutional investors. Comparatively, 38.4% of I-Mab shares are held by institutional investors. 22.1% of I-Mab shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
I-Mab has a consensus price target of $12.25, suggesting a potential upside of 576.80%. Given InterCure's higher possible upside, analysts clearly believe I-Mab is more favorable than InterCure.
Summary
I-Mab beats InterCure on 6 of the 11 factors compared between the two stocks.
Get I-Mab News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
